A Study to Evaluate AMG 162 in the Treatment of Postmenopausal Osteoporosis

This study will evaluate the effectiveness and safety of AMG 162 in treating women with Postmenopausal Osteoporosis.

Official Title

Conditions

Osteoporosis

Study Type

Interventional

Study Design

Treatment

Further Details

Primary Outcome Measures:

• Reduction in the number of new vertebral fractures in post menopausal osteoporotic women treated with AMG 162 compared to placebo.

Secondary Outcome Measures:

• Characterize the safety and tolerability of AMG 162 in this patient population.

Study Start

Eligibility & Criteria

• Ages Eligible for Study: 60 Years – 90 Years
• Genders Eligible for Study: Female

Total Enrolment

Contact Details

Australian Locations:

• Woolloongabba, Australia
• Parkville, Australia
• Geelong, Australia
• St. Leonards,New South Wales, Australia

For more information, refer to Amgen Clinical Trials

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.